Full-Time

Laboratory Animal Care Technician III

Tues-Sat

Inotiv

Inotiv

1,001-5,000 employees

Global CRO for life sciences research

Compensation Overview

$21 - $25/hr

Fort Collins, CO, USA

In Person

Regular on-site attendance is required, with travel between the ranch and in-town facilities.

Associate's

Category
Medical, Clinical & Veterinary (1)
Required Skills
Microsoft Office
Inventory Management

Get referred to Inotiv

See people who can refer or advise you

Requirements
  • A high school diploma or equivalent is required.
  • Two years of animal handling and care experience in a laboratory or veterinary setting are required.
  • One year of experience with a variety of species, including large animals, is required.
  • Demonstrated independent user proficiency with Microsoft Office Suite or related software, data capture software, and similar computer applications is required.
  • Ability to regularly lift up to 50 pounds and move heavy equipment safely.
  • Ability to stand and move throughout an entire work shift, including walking, bending, reaching, lifting, crouching, pushing, and pulling.
  • Manual dexterity to operate necessary equipment and perform the essential tasks outlined in the position description.
  • Close visual acuity and depth perception are required, with or without glasses or contact lenses.
  • Use of provided personal protective equipment is required.
  • Regular on-site attendance as scheduled by management is required.
  • Ability to travel to various site locations.
  • Ability to operate typical farm and mechanical equipment, including tractors or loaders, skid steers, trucks with stock or dump trailers, and bumper-pull or gooseneck trailers; ability to back trucks and trailers.
  • Ability to follow detailed instructions and understand scientific protocols and reports using scientific methods.
  • Ability and willingness to learn new methods or workflows and participate in continual training.
  • Ability to maintain compliance with safety regulations, Good Laboratory Practices, United States Department of Agriculture, Association for Assessment and Accreditation of Laboratory Animal Care, Office of Laboratory Animal Welfare, and other applicable regulations.
Responsibilities
  • Perform routine husbandry, including feeding, watering, and cleaning pens, for various animal species.
  • Perform general room cleaning, animal husbandry sanitization, and water monitoring.
  • Ensure animals have adequate space, safe and secure housing, and appropriate enrichment.
  • Monitor temperature and humidity in animal rooms and report heating, ventilation, and air conditioning issues.
  • Complete daily animal welfare and mortality checks and animal husbandry records.
  • Perform pest monitoring for rodents and insects.
  • Transport animals for acquisition and disposal using the company pickup truck and trailers.
  • Monitor inventory of animal care supplies, check expiration dates, notify the supervisor when items need to be ordered, and assist with stocking supplies.
  • Perform routine cleaning tasks within the animal vivarium, including sweeping, mopping, and trash removal.
  • Review study protocols and notebooks before study initiation and participate in pre-study meetings as needed.
  • Assist with in-life study procedures and raw data collection according to study protocols and standard operating procedures.
  • Complete accurate and timely entries in the electronic data capture system or on paper records.
  • Perform animal receiving procedures, including preparing cage cards, conducting entry and study-start physical examinations, and completing animal receipt records.
  • Restrain various animal species for treatments and procedures.
  • Handle animals for euthanasia procedures.
  • Perform clinical observations of animals and their pens or cages to assess well-being, health, and sanitation.
  • Review paperwork and computer entries daily for completeness, legibility, and accuracy.
  • Collect body weights and body condition scores.
  • Assist with study acclimation, including leash and collar training.
  • Mentor and assist with training junior technicians, provide guidance on best practices, serve as a resource for questions, and model successful behaviors.
  • Operate ranch and agricultural equipment, including a gator, skid steer, and dump trailer.
  • Collect feed consumption weights.
  • Learn animal dosing procedures through ocular, oral capsule, topical, subcutaneous, intramuscular, oral gavage, and intravenous routes across multiple species.
  • Learn to administer treatments to various species.
  • Learn to collect and process blood, urine, and fecal samples.
  • Assist with euthanizing animals.
  • Follow standard operating procedures and applicable laboratory or company policies and procedures.
  • Maintain confidential information.
  • Support and participate in company initiatives as directed.
  • Review applicable standard operating procedures periodically to ensure accuracy and compliance.
  • Complete assigned training requirements and maintain appropriate training documentation.
  • Maintain safety compliance and good documentation practices.
  • Perform other duties as assigned.
Desired Qualifications
  • An associate or higher degree in animal science or a related field is preferred.
  • Experience operating farm machinery and equipment, including skid steers, gators, tractors, and trailers, is preferred.
  • American Association for Laboratory Animal Science certification is preferred.

Inotiv provides contract research services across drug discovery, preclinical testing, analytical testing, and related areas for the pharmaceutical and biotech industries. Its offerings combine analytical chemistry, preclinical research, and access to a broad set of research models to generate data and prepare regulatory-compliant documentation that supports drug development, safety testing, and medical device evaluation. The company differentiates itself through an integrated CRO model that pairs BASi’s analytical capabilities, Seventh Wave’s preclinical work, and Envigo’s research models in one end-to-end service. Its goal is to be a global partner for drug discovery, safety assessment, and product development by delivering scalable research services and regulatory-grade data to biopharma and medical device customers.

Company Size

1,001-5,000

Company Stage

IPO

Headquarters

West Lafayette, Indiana

Founded

1974

Get referred to Inotiv

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • July 20, 2026 restructuring improved liquidity and strengthened Inotiv's balance sheet.
  • Q1 fiscal 2026 backlog reached $145.4 million, supporting near-term DSA revenue visibility.
  • Management kept normal operations through bankruptcy, preserving clients, vendors, and service continuity.

What critics are saying

  • June 2026 Chapter 11 cancelled existing equity, wiping out prior shareholders.
  • USDA cited Inotiv facilities in April 2026 and August 2026 for critical violations.
  • Animal-welfare scandals and bankruptcy stigma threaten customer trust and future contract wins.

What makes Inotiv unique

  • Inotiv pairs preclinical CRO services with research models and analytical capabilities.
  • July 2026 emergence from Chapter 11 cut about $326 million of debt.
  • Its VUGENE collaboration adds AI bioinformatics across Discovery and Translational Sciences.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Pension

Life Insurance

Wellbeing Program

Paid Time Off

401(k) Retirement Plan

Flexible Work Hours

Remote Work Options

Stock Options

Company Equity

Conference Attendance Budget

Professional Development Budget

Family Planning Benefits

Fertility Treatment Support

Parental Leave

Paid Holidays

Short-term Disability

Long-term Disability

Dental Insurance

Vision Insurance

Phone/Internet Stipend

Home Office Stipend

Paid Vacation

Paid Sick Leave

Flexible Benefits Scheme

Employee Assistance Program

Private Health Insurance

Health cash plan

Retail discounts

Education allowance

Tuition Reimbursement

Meal Benefits

Adoption Assistance

Growth & Insights and Company News

Headcount

6 month growth

19%

1 year growth

19%

2 year growth

19%
Pryor Cashman
Jun 22nd, 2026
Pryor Cashman represents Acquiom Agency Services as DIP Agent and administrative and collateral in Inotiv Chapter 11 cases.

Pryor Cashman represents Acquiom Agency Services as DIP Agent and administrative and collateral in Inotiv Chapter 11 cases. Pryor Cashman has been engaged as counsel to Acquiom Agency Services LLC ("Acquiom"), in its roles as (i) DIP Agent for the Debtor-in-Possession Loan Credit Agreement, and (ii) administrative and collateral agent under the Prepetition First Lien Credit Agreement in the Chapter 11 bankruptcy cases of Inotiv, Inc. ("Inotiv") and its affiliated debtors. Inotiv is a contract research organization that provides drug discovery and development services to the pharmaceutical and medical device industries. On June 3, 2026, Inotiv and certain of its affiliates filed for bankruptcy protection in the United States Bankruptcy Court for the Southern District of Texas. The Pryor Cashman team representing Acquiom includes Partner Seth H. Lieberman, Chair of the Bankruptcy, Reorganization, and Creditors' Rights Group and Co-Chair of the Corporate Trust Practice; Partner Patrick Sibley, Co-Chair of the Corporate Trust Practice; Partner David W. Smith; Counsels Arsala Kidwai and Andrew S. Richmond; and Associate Daniel Brenner.seth Related people. Related services & industries. Firm Highlights Slide 1 of 10

Inotiv
Jun 3rd, 2026
Inotiv Reaches Agreement to Strengthen Capital Structure and Position Company for Future Growth

Receives commitments for $65 million in new money financing to support ongoing business operations Recapitalization effectuated through a pre-packaged plan of reorganization on an expedited basis Transaction is supported by substantially all of the Company’s existing lenders Normal business operations will continue seamlessly with no impact on vendors and suppliers Inotiv, Inc. (NASDAQ: NOTV) (the “Company”, or “Inotiv”), a leading Contract Research Organization specializing in nonclinical and analytical drug discovery and development services and research models and related products and services, today announced that it has entered into a Restructuring Support Agreement (“RSA”) with its Prepetition First Lien Lenders and Ad Hoc Group of Noteholders, constituting substantially all of its junior creditors, to implement a comprehensive recapitalization transaction that will strengthen its capital structure. To implement the transaction, Inotiv has filed a voluntary, prepackaged chapter

StockTitan
Dec 11th, 2025
Inotiv Partners with VUGENE to Advance AI-Driven Drug Discovery and Bioinformatics Capabilities

Inotiv partners with VUGENE to advance ai-driven drug Discovery and bioinformatics capabilities. Rhea-AI summary. Inotiv (NASDAQ: NOTV) announced a strategic collaboration with VUGENE on December 11, 2025 to integrate VUGENE's cloud-based AI/ML multi-omics bioinformatics platform into Inotiv's Discovery & Translational Sciences Division. The partnership aims to accelerate AI-assisted drug discovery by improving interpretation of epigenomic, proteomic, and other molecular datasets to better predict drug efficacy and safety in early-stage research. Inotiv said the integration will enable more efficient, data-driven decision making for client discovery programs, while VUGENE expects broader application of its computational technologies in real-world research settings. News market reaction 1 alert. On the day this news was published, NOTV declined 4.48%, reflecting a moderate negative market reaction. Data tracked by StockTitan Argus on the day of publication. Technical Shares at 0.8414 are trading below the 200-day MA of 1.87 and 87.02% under the 52-week high. Peers on Argus 1 down. Sector peers show mixed moves, with ADVB down 9.61% and others modestly up or down. With only one peer in momentum and no shared news, the AI-focused partnership appears company-specific rather than part of a sector-wide move. Historical context. | Date | Event | Sentiment | Move | Catalyst | | Dec 03 | Earnings report | Positive | +8.1% | Reported FY2025 revenue growth and sharply reduced operating loss. | | Nov 25 | Growth ranking | Positive | +3.9% | Ranked 182nd on Deloitte Technology Fast 500 with 448% growth. | | Nov 21 | Earnings date notice | Neutral | -3.9% | Announced timing and access details for FY2025 results call. | | Nov 17 | Preliminary results | Positive | -33.2% | Shared preliminary FY2025 revenue and strong DSA growth metrics. | | Oct 21 | Conference participation | Neutral | -2.2% | Outlined participation in multiple November investor conferences. | Operationally positive news has sometimes aligned with gains but also seen sharp selloffs, indicating inconsistent market confidence in updates. Over the last few months, Inotiv reported improving FY2025 results with Q4 revenue of $138.1M and FY revenue of $513.0M, alongside a narrowed operating loss of $30.9M. Recognition on the 2025 Deloitte Technology Fast 500(TM) and strong DSA growth, with backlog around $138M, highlight expansion. However, preliminary results on Nov 17, 2025 coincided with a -33.2% move, contrasting with the later earnings-day gain of 8.13%. Today's AI partnership adds to a pattern of strategic initiatives amid volatile reactions. Regulatory & risk context. An effective S-3 shelf filed on 2025-08-29 allows future securities offerings, including an at-the-market equity program with up to 3.0% commission. The filing highlights an auditor's explanatory paragraph raising substantial doubt about going-concern status, material weaknesses in internal control, and warns of immediate dilution risk and variable ATM proceeds. Market pulse summary. This announcement details a strategic collaboration integrating VUGENE's AI-enabled bioinformatics platform into Inotiv's Discovery & Translational Sciences Division to better analyze complex epigenomic and proteomic data. It follows FY2025 revenue of $513.0M and recognition in the 2025 Deloitte Technology Fast 500(TM). Regulatory filings, including the 2025-08-29 S-3, highlight going-concern language, internal-control weaknesses, and dilution risk. Investors may watch how this AI partnership translates into Discovery and Safety Assessment growth and backlog trends.

StockTitan
Dec 23rd, 2024
Inotiv Raises $24M in Equity Offering

Inotiv completed an equity offering, raising approximately $24 million by selling 6 million common shares at $4.25 each. The offering closed on December 19, 2024, with Lake Street Capital Markets as the sole book-running manager. An option allows underwriters to purchase up to 900,000 additional shares until January 17, 2025. The funds will be used for working capital, capital expenditures, and general corporate purposes to enhance financial flexibility and support strategic initiatives.

GlobeNewswire
Dec 18th, 2024
Inotiv, Inc. Announces Pricing of Public Offering of 6,000,000 Common Shares

WEST LAFAYETTE, Ind., Dec. 18, 2024 (GLOBE NEWSWIRE) -- Inotiv, Inc. (Nasdaq: NOTV) (the “Company”), a leading contract research organization...